health · HHS-NIH11

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

National Institutes of Health · PAR-25-374

620 days left

Award Range

$0 – $1.0M

Total Program Funding

$1.0M

Deadline

May 7, 2028

GRANTQUICK SUMMARYPlain-English Overview

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed). National Institutes of Health. This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be... up to $1,000,000 per award; $1,000,000 total program funding.

Who Should Apply

Public universities/colleges, Nonprofits (non-501c3), Private universities/colleges, State governments, Other eligible entities (+10 more)

Who Should NOT Apply

Organizations not matching the eligible applicant types listed above

Key Requirements (Plain English)

•Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Is...
•Deadline: 2028-05-07

💡 GrantQuick Tip

Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.

Competitiveness: Moderate to high — federal grants are always competitive

What This Grant Funds

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.

Attachments

PDF

PAR-25-374 Full Announcement Text

PAR-25-374-Full-Announcement.html

Who Can Apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Eligible Applicant Types

Public Colleges & UniversitiesNonprofits without 501(c)(3)Private Colleges & UniversitiesState GovernmentsOther (see NOFO for details)Independent School DistrictsFor-Profit OrganizationsCounty GovernmentsPublic And Indian Housing AuthoritiesSmall BusinessesSpecial District GovernmentsFederally Recognized Tribal Governments501(c)(3) NonprofitsOther Tribal OrganizationsCity/Township Governments

Funding Details

Maximum Award: $1.0M
Total Program Funding: $1.0M
Cost Sharing Required?: No
Funding Instrument: grant

Key Dates

Posted: December 30, 2024

Application Deadline: May 7, 2028 (620 days remaining)

Agency Contact

NIH Grants Information grantsinfo@nih.gov

grantsinfo@nih.gov

Ready to apply?

View the full NOFO and submit your application on Grants.gov

View on Grants.gov